Page last updated: 2024-10-23

aspirin and Gestational Hypertension

aspirin has been researched along with Gestational Hypertension in 62 studies

Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.

Research Excerpts

ExcerptRelevanceReference
"To assess the impact of low-dose aspirin (LDA) starting in early pregnancy on delaying preterm hypertensive disorders of pregnancy."9.69Aspirin delays the onset of hypertensive disorders of pregnancy among nulliparous pregnant women: A secondary analysis of the ASPIRIN trial. ( Bauserman, M; Bucher, S; Carlo, WA; Chomba, E; Das, P; Derman, RJ; Esamai, F; Figueroa, L; Goco, N; Goldenberg, RL; Goudar, SS; Hibberd, PL; Hoffman, MK; Jessani, S; Kavi, A; Koso-Thomas, M; Krebs, NF; Lokangaka, A; McClure, EM; Metgud, MC; Moore, J; Mwenechanya, M; Nielsen, E; Patel, A; Saleem, S; Silver, R; Somannavar, MS; Tshefu, A, 2023)
"This study aimed to compare how low-dose aspirin differentially benefits nulliparous women with and without additional preeclampsia risk factors for the prevention of preterm birth and hypertensive disorders of pregnancy."9.69The impact of risk factors on aspirin's efficacy for the prevention of preterm birth. ( Achieng, E; Bauserman, M; Bucher, S; Carlo, WA; Chomba, E; Das, P; Derman, RJ; Esamai, F; Figueroa, L; Goco, N; Goldenberg, RL; Goudar, SS; Hemingway-Foday, J; Hibberd, PL; Hoffman, MK; Jessani, S; Kavi, A; Krebs, NF; Kurhe, K; Liechty, EA; Lokangaka, A; McClure, EM; Metgud, M; Moore, J; Nuss, EE; Nyongesa, P; Okitawutshu, J; Saleem, S; Silver, RM; Somannavar, M; Tembo, AM; Tshefu, A, 2023)
" The secondary outcomes included gestational hypertension; fetal growth restriction; preterm birth, either spontaneous or iatrogenic, before 34 weeks of gestation; gestational age at birth; neonatal birthweight; and adverse events secondary to the administration of aspirin, including antepartum and postpartum hemorrhage."9.41Aspirin for prevention of preeclampsia and adverse perinatal outcome in twin pregnancies: a systematic review and meta-analysis. ( Acuti Martellucci, C; Buca, D; Cerra, C; D'Antonio, F; Fichera, A; Flacco, ME; Herrera, M; Khalil, A; Morelli, R; Orabona, R; Prefumo, F; Rizzo, G, 2023)
"Compared with aspirin alone, low-dose aspirin combined with calcium supplementation was more effective in preventing preeclampsia, reduced the risk of preterm birth and postpartum hemorrhage, and promoted fetal growth."9.41Clinical efficacy of low-dose aspirin combined with calcium in preventing preeclampsia: A systematic review and meta-analysis. ( Chen, WY; Sun, SF, 2023)
"This study aimed to evaluate the maternal and fetal results in women undergoing antihypertensive therapy (low aspirin or labetalol) with mild to severe chronic hypertension relative to women without medicines."9.34Treatment of pregnancy-induced hypertension compared with labetalol, low dose aspirin and placebo. ( Wang, F; Xiang, X; Zhao, N; Zhou, Z, 2020)
"To examine whether combined treatment with low-molecular-weight heparin (LMWH) and aspirin reduces recurrent hypertensive disorders of pregnancy (HD: pre-eclampsia, eclampsia or HELLP syndrome) in women with antiphospholipid antibodies (aPLA) and a previous delivery for HD and/or small-for-gestational-age (SGA) birthweight before 34 weeks gestation."9.22Low-molecular-weight heparin and aspirin in the prevention of recurrent early-onset pre-eclampsia in women with antiphospholipid antibodies: the FRUIT-RCT. ( Bezemer, D; de Vries, JI; Hague, WM; van Hoorn, ME; van Pampus, MG, 2016)
"The comparison of clinical outcome showed that the incidents of pregnancy-induced hypertension syndrome, pre-eclampsia and eclampsia of aspirin group were significantly lower than that of the placebo group (p<0."9.22Effect of regular oral intake of aspirin during pregnancy on pregnancy outcome of high-risk pregnancy-induced hypertension syndrome patients. ( Li, L; Liu, FM; Wang, M; Yang, HL; Zhao, M, 2016)
"This pilot trial demonstrates that both furosemide and amlodipine might have the same effect during pregnancy."9.19Management of chronic hypertension during pregnancy with furosemide, amlodipine or aspirin: a pilot clinical trial. ( Dominguez, L; Solis, A; Vigil-De Gracia, P, 2014)
"The incidence of hypertensive complications was significantly lower in the group of women treated with low-dose aspirin throughout IVF treatment and first trimester of pregnancy."9.14Lower incidence of hypertensive complications during pregnancy in patients treated with low-dose aspirin during in vitro fertilization and early pregnancy. ( Groeneveld, E; Homburg, R; Hompes, PG; Hoozemans, DA; Lambalk, CB; Lambers, MJ; Schats, R, 2009)
"In the present study, the incidence of hypertensive pregnancy complications did not differ statistically significantly between low-dose aspirin and placebo groups in unselected IVF/ICSI patients, when medication was started concomitantly with gonadotrophin stimulation and continued until delivery."9.14Low-dose aspirin therapy and hypertensive pregnancy complications in unselected IVF and ICSI patients: a randomized, placebo-controlled, double-blind study. ( Haapsamo, M; Heinonen, S; Martikainen, H; Nuojua-Huttunen, S; Räsänen, J; Tinkanen, H, 2010)
"Benefits of aspirin administration on pre-eclampsia and IUGR depend on the gestational age and dose of aspirin administration."9.05Prophylactic aspirin for preventing pre-eclampsia and its complications: An overview of meta-analyses. ( Banach, M; Ghazanfarpour, M; Jamialahmadi, T; Sahebkar, A; Sathyapalan, T, 2020)
"Delivery after US Preventive Services Taskforce aspirin guideline publication was associated with higher rates of hypertensive disorders of pregnancy and preterm birth in a population of individuals with diabetes mellitus."8.31Hypertensive disorders of pregnancy pre- and postaspirin guideline publication in individuals with pregestational diabetes mellitus. ( Allshouse, AA; Bruno, AM; Metz, TD; Theilen, LH, 2023)
"The objective of this study is to investigate possible changes in aspirin resistance during and after pregnancy over time."7.96Resistance of aspirin during and after pregnancy: A longitudinal cohort study. ( Abheiden, CNH; Bij de Weg, JM; de Boer, MA; de Vries, JIP; Fuijkschot, WW; Harmsze, AM; Thijs, A, 2020)
"To elucidate patients' knowledge and counseling perspective on aspirin reducing the risk of hypertensive disorders of pregnancy (HDP)."7.96Patients' perspective on aspirin during pregnancy: a survey. ( Abheiden, CNH; Bij de Weg, JM; de Boer, MA; de Groot, C; de Vries, JIP, 2020)
"The effect and safety of magnesium sulfate combined with low-dose aspirin in the treatment of pregnancy induced hypertension were assessed by summarizing the related randomized controlled trials."7.96Efficacy and safety of low dose aspirin and magnesium sulfate in the treatment of pregnancy induced hypertension: A protocol for systematic review and meta-analysis. ( Chen, M; Chen, Y; He, G; Liu, X, 2020)
"Aspirin use in pregnancy reduces the risks of maternal hypertensive disorders."7.91Aspirin use during pregnancy and hypertensive disorders in women with various risks. ( Chen, C; Jing, S; Lu, D; Xie, H; Zhang, J; Zhu, J, 2019)
"To determine whether hypertensive disorders of pregnancy (HDP) increased long-term stroke risk in women in the California Teachers Study (CTS), a prospective cohort study, and whether aspirin or statin use modified this risk."7.91Aspirin reduces long-term stroke risk in women with prior hypertensive disorders of pregnancy. ( Bello, NA; Boehme, AK; Chung, NT; Elkind, MSV; Lacey, JV; Lakshminarayan, K; Miller, EC; Wang, SS; Wapner, R; Willey, JZ; Woo, D; Zhong, C, 2019)
"Low-dose aspirin has been used during pregnancy, most commonly to prevent or delay the onset of preeclampsia."7.88ACOG Committee Opinion No. 743: Low-Dose Aspirin Use During Pregnancy. ( , 2018)
"Low-dose aspirin has been used during pregnancy, most commonly to prevent or delay the onset of preeclampsia."7.88ACOG Committee Opinion No. 743 Summary: Low-Dose Aspirin Use During Pregnancy. ( , 2018)
"The FRUIT-RCT concluded that low-molecular-weight heparin added to aspirin compared to treatment with aspirin alone is beneficial in the prevention of early-onset hypertensive disorders of pregnancy (HD) in women with inheritable thrombophilia and prior HD and/or a small-for-gestational age (SGA) infant leading to delivery before 34 weeks gestation."7.85Post-pregnancy aspirin resistance appears not to be related with recurrent hypertensive disorders of pregnancy. ( Abheiden, CNH; Arduç, A; de Boer, MA; de Vries, JIP; Fuijkschot, WW; Harmsze, AM; Thijs, A; van Diemen, JJK, 2017)
"Preeclampsia is a hypertensive disease unique to pregnancy and has a significant impact on maternal and neonatal morbidity and mortality."5.72Assessment of adherence to aspirin for preeclampsia prophylaxis and reasons for nonadherence. ( Olson, DN; Ranzini, AC; Russell, T, 2022)
"To assess the impact of low-dose aspirin (LDA) starting in early pregnancy on delaying preterm hypertensive disorders of pregnancy."5.69Aspirin delays the onset of hypertensive disorders of pregnancy among nulliparous pregnant women: A secondary analysis of the ASPIRIN trial. ( Bauserman, M; Bucher, S; Carlo, WA; Chomba, E; Das, P; Derman, RJ; Esamai, F; Figueroa, L; Goco, N; Goldenberg, RL; Goudar, SS; Hibberd, PL; Hoffman, MK; Jessani, S; Kavi, A; Koso-Thomas, M; Krebs, NF; Lokangaka, A; McClure, EM; Metgud, MC; Moore, J; Mwenechanya, M; Nielsen, E; Patel, A; Saleem, S; Silver, R; Somannavar, MS; Tshefu, A, 2023)
"This study aimed to compare how low-dose aspirin differentially benefits nulliparous women with and without additional preeclampsia risk factors for the prevention of preterm birth and hypertensive disorders of pregnancy."5.69The impact of risk factors on aspirin's efficacy for the prevention of preterm birth. ( Achieng, E; Bauserman, M; Bucher, S; Carlo, WA; Chomba, E; Das, P; Derman, RJ; Esamai, F; Figueroa, L; Goco, N; Goldenberg, RL; Goudar, SS; Hemingway-Foday, J; Hibberd, PL; Hoffman, MK; Jessani, S; Kavi, A; Krebs, NF; Kurhe, K; Liechty, EA; Lokangaka, A; McClure, EM; Metgud, M; Moore, J; Nuss, EE; Nyongesa, P; Okitawutshu, J; Saleem, S; Silver, RM; Somannavar, M; Tembo, AM; Tshefu, A, 2023)
"Compared with aspirin alone, low-dose aspirin combined with calcium supplementation was more effective in preventing preeclampsia, reduced the risk of preterm birth and postpartum hemorrhage, and promoted fetal growth."5.41Clinical efficacy of low-dose aspirin combined with calcium in preventing preeclampsia: A systematic review and meta-analysis. ( Chen, WY; Sun, SF, 2023)
"Low-molecular-weight heparin, vitamin D supplementation, exercise, calcium supplementation, and aspirin reduce the risk of preeclampsia/pregnancy-induced hypertension."5.41Comparative effectiveness of prophylactic strategies for preeclampsia: a network meta-analysis of randomized controlled trials. ( Chen, JY; Duan, CY; He, PC; Li, JQ; Liu, YH; Liu, YX; Lye, S; Tan, N; Wang, ZJ; Wei, YX; Xie, NJ; Xu, XJ; Zhang, YS, 2023)
" The secondary outcomes included gestational hypertension; fetal growth restriction; preterm birth, either spontaneous or iatrogenic, before 34 weeks of gestation; gestational age at birth; neonatal birthweight; and adverse events secondary to the administration of aspirin, including antepartum and postpartum hemorrhage."5.41Aspirin for prevention of preeclampsia and adverse perinatal outcome in twin pregnancies: a systematic review and meta-analysis. ( Acuti Martellucci, C; Buca, D; Cerra, C; D'Antonio, F; Fichera, A; Flacco, ME; Herrera, M; Khalil, A; Morelli, R; Orabona, R; Prefumo, F; Rizzo, G, 2023)
"This study aimed to evaluate the maternal and fetal results in women undergoing antihypertensive therapy (low aspirin or labetalol) with mild to severe chronic hypertension relative to women without medicines."5.34Treatment of pregnancy-induced hypertension compared with labetalol, low dose aspirin and placebo. ( Wang, F; Xiang, X; Zhao, N; Zhou, Z, 2020)
"The comparison of clinical outcome showed that the incidents of pregnancy-induced hypertension syndrome, pre-eclampsia and eclampsia of aspirin group were significantly lower than that of the placebo group (p<0."5.22Effect of regular oral intake of aspirin during pregnancy on pregnancy outcome of high-risk pregnancy-induced hypertension syndrome patients. ( Li, L; Liu, FM; Wang, M; Yang, HL; Zhao, M, 2016)
"To examine whether combined treatment with low-molecular-weight heparin (LMWH) and aspirin reduces recurrent hypertensive disorders of pregnancy (HD: pre-eclampsia, eclampsia or HELLP syndrome) in women with antiphospholipid antibodies (aPLA) and a previous delivery for HD and/or small-for-gestational-age (SGA) birthweight before 34 weeks gestation."5.22Low-molecular-weight heparin and aspirin in the prevention of recurrent early-onset pre-eclampsia in women with antiphospholipid antibodies: the FRUIT-RCT. ( Bezemer, D; de Vries, JI; Hague, WM; van Hoorn, ME; van Pampus, MG, 2016)
" The following were consistently recommended: (1) automated blood pressure measurement with devices validated for pregnancy and preeclampsia, reflecting increasing recognition of the prevalence of white-coat hypertension and the potential usefulness of home blood pressure monitoring; (2) use of dipstick proteinuria testing for screening followed by quantitative testing by urinary protein-to-creatinine ratio or 24-hour urine collection; (3) key definitions and most aspects of classification, including a broad definition of preeclampsia (which includes proteinuria and maternal end-organ dysfunction, including headache and visual symptoms and laboratory abnormalities of platelets, creatinine, or liver enzymes) and a recognition that it can worsen after delivery; (4) preeclampsia prevention with aspirin; (5) treatment of severe hypertension, most commonly with intravenous labetalol, oral nifedipine, or intravenous hydralazine; (6) treatment for nonsevere hypertension when undertaken, with oral labetalol (in particular), methyldopa, or nifedipine, with recommendations against the use of renin-angiotensin-aldosterone inhibitors; (7) magnesium sulfate for eclampsia treatment and prevention among women with "severe" preeclampsia; (8) antenatal corticosteroids for preterm birth but not hemolysis, elevated liver enzymes, and low platelet count syndrome; (9) delivery at term for preeclampsia; (10) a focus on usual labor and delivery care but avoidance of ergometrine; and (11) an appreciation that long-term health complications are increased in incidence, mandating lifestyle change and risk factor modification."5.22Guidelines-similarities and dissimilarities: a systematic review of international clinical practice guidelines for pregnancy hypertension. ( Gillon, TE; Magee, LA; Pels, A; Scott, G; von Dadelszen, P, 2022)
"This pilot trial demonstrates that both furosemide and amlodipine might have the same effect during pregnancy."5.19Management of chronic hypertension during pregnancy with furosemide, amlodipine or aspirin: a pilot clinical trial. ( Dominguez, L; Solis, A; Vigil-De Gracia, P, 2014)
"The incidence of hypertensive complications was significantly lower in the group of women treated with low-dose aspirin throughout IVF treatment and first trimester of pregnancy."5.14Lower incidence of hypertensive complications during pregnancy in patients treated with low-dose aspirin during in vitro fertilization and early pregnancy. ( Groeneveld, E; Homburg, R; Hompes, PG; Hoozemans, DA; Lambalk, CB; Lambers, MJ; Schats, R, 2009)
"In the present study, the incidence of hypertensive pregnancy complications did not differ statistically significantly between low-dose aspirin and placebo groups in unselected IVF/ICSI patients, when medication was started concomitantly with gonadotrophin stimulation and continued until delivery."5.14Low-dose aspirin therapy and hypertensive pregnancy complications in unselected IVF and ICSI patients: a randomized, placebo-controlled, double-blind study. ( Haapsamo, M; Heinonen, S; Martikainen, H; Nuojua-Huttunen, S; Räsänen, J; Tinkanen, H, 2010)
"Benefits of aspirin administration on pre-eclampsia and IUGR depend on the gestational age and dose of aspirin administration."5.05Prophylactic aspirin for preventing pre-eclampsia and its complications: An overview of meta-analyses. ( Banach, M; Ghazanfarpour, M; Jamialahmadi, T; Sahebkar, A; Sathyapalan, T, 2020)
"Delivery after US Preventive Services Taskforce aspirin guideline publication was associated with higher rates of hypertensive disorders of pregnancy and preterm birth in a population of individuals with diabetes mellitus."4.31Hypertensive disorders of pregnancy pre- and postaspirin guideline publication in individuals with pregestational diabetes mellitus. ( Allshouse, AA; Bruno, AM; Metz, TD; Theilen, LH, 2023)
"To elucidate patients' knowledge and counseling perspective on aspirin reducing the risk of hypertensive disorders of pregnancy (HDP)."3.96Patients' perspective on aspirin during pregnancy: a survey. ( Abheiden, CNH; Bij de Weg, JM; de Boer, MA; de Groot, C; de Vries, JIP, 2020)
"The objective of this study is to investigate possible changes in aspirin resistance during and after pregnancy over time."3.96Resistance of aspirin during and after pregnancy: A longitudinal cohort study. ( Abheiden, CNH; Bij de Weg, JM; de Boer, MA; de Vries, JIP; Fuijkschot, WW; Harmsze, AM; Thijs, A, 2020)
"The effect and safety of magnesium sulfate combined with low-dose aspirin in the treatment of pregnancy induced hypertension were assessed by summarizing the related randomized controlled trials."3.96Efficacy and safety of low dose aspirin and magnesium sulfate in the treatment of pregnancy induced hypertension: A protocol for systematic review and meta-analysis. ( Chen, M; Chen, Y; He, G; Liu, X, 2020)
"To determine whether hypertensive disorders of pregnancy (HDP) increased long-term stroke risk in women in the California Teachers Study (CTS), a prospective cohort study, and whether aspirin or statin use modified this risk."3.91Aspirin reduces long-term stroke risk in women with prior hypertensive disorders of pregnancy. ( Bello, NA; Boehme, AK; Chung, NT; Elkind, MSV; Lacey, JV; Lakshminarayan, K; Miller, EC; Wang, SS; Wapner, R; Willey, JZ; Woo, D; Zhong, C, 2019)
"Calcium and low-dose aspirin are two potential approaches for primary prevention of hypertensive disorders of pregnancy (HDP)."3.91Views and preferences of medical professionals and pregnant women about a novel primary prevention intervention for hypertensive disorders of pregnancy: a qualitative study. ( Bekker, MN; Browne, JL; Crombag, NMT; Franx, A; Grobbee, DE; van der Graaf, R; Vestering, A, 2019)
"Aspirin use in pregnancy reduces the risks of maternal hypertensive disorders."3.91Aspirin use during pregnancy and hypertensive disorders in women with various risks. ( Chen, C; Jing, S; Lu, D; Xie, H; Zhang, J; Zhu, J, 2019)
"To use the Theory of Planned Behavior (TPB) combined with action and coping planning plus global relationship with husband to explain the aspirin adherence in a sample of women with high-risk pregnancy."3.88Using extended theory of planned behavior to understand aspirin adherence in pregnant women. ( Broström, A; Lin, CY; Nilsen, P; Pakpour, AH, 2018)
"Low-dose aspirin has been used during pregnancy, most commonly to prevent or delay the onset of preeclampsia."3.88ACOG Committee Opinion No. 743 Summary: Low-Dose Aspirin Use During Pregnancy. ( , 2018)
"Low-dose aspirin has been used during pregnancy, most commonly to prevent or delay the onset of preeclampsia."3.88ACOG Committee Opinion No. 743: Low-Dose Aspirin Use During Pregnancy. ( , 2018)
"The FRUIT-RCT concluded that low-molecular-weight heparin added to aspirin compared to treatment with aspirin alone is beneficial in the prevention of early-onset hypertensive disorders of pregnancy (HD) in women with inheritable thrombophilia and prior HD and/or a small-for-gestational age (SGA) infant leading to delivery before 34 weeks gestation."3.85Post-pregnancy aspirin resistance appears not to be related with recurrent hypertensive disorders of pregnancy. ( Abheiden, CNH; Arduç, A; de Boer, MA; de Vries, JIP; Fuijkschot, WW; Harmsze, AM; Thijs, A; van Diemen, JJK, 2017)
"This prospective study aimed to evaluate pregnancy outcome and complications in women with recurrent pregnancy loss (RPL) and protein S (PS) deficiency, who received low dose aspirin (LDA) or LDA plus heparin (LDA/H) therapies."3.83Protein S deficiency complicated pregnancy in women with recurrent pregnancy loss. ( Deguchi, M; Ebina, Y; Morizane, M; Shinozaki, N; Tanimura, K; Yamada, H, 2016)
"Aspirin reduces the risk of recurrent hypertensive disorders of pregnancy (HD) and fetal growth restriction (FGR)."3.83Aspirin adherence during high-risk pregnancies, a questionnaire study. ( Abheiden, CN; de Boer, MA; de Vries, JI; Fuijkschot, WW; Thijs, A; van Reuler, AV, 2016)
"The aim of this study was to evaluate whether low doses of aspirin (100 mg per day) administered to a homogeneous population of women early (8-10 weeks) during their first pregnancy improved the outcome of gestation hypertensive disorders."3.77Prevention of gravidic endothelial hypertension by aspirin treatment administered from the 8th week of gestation. ( Bakhti, A; Vaiman, D, 2011)
"Preeclampsia and gestational hypertension are common pregnancy complications associated with adverse maternal and child outcomes."3.01Polygenic prediction of preeclampsia and gestational hypertension. ( Antopia, MC; Bhatta, L; Brumpton, BM; Cho, SMJ; Do, R; Gray, KJ; Guerrero, RF; Gupta, RM; Haas, DM; Honigberg, MC; Khan, RR; Koyama, S; Laisk, T; Martin, HC; Nadkarni, GN; Natarajan, P; Patel, AP; Patil, S; Pe'er, I; Saxena, R; Schuermans, A; Selvaraj, MS; Trinder, M; Truong, B; Urbut, SM; van Heel, DA; Vellarikkal, SK; Verma, SS; Vy, HMT; Xiao, B; Yan, Q; Zöllner, S, 2023)
"Preeclampsia and gestational hypertension are common complications of pregnancy associated with significant maternal and infant morbidity."2.94Preconception Blood Pressure and Its Change Into Early Pregnancy: Early Risk Factors for Preeclampsia and Gestational Hypertension. ( Andriessen, VC; Connell, M; Kim, K; Mendola, P; Mumford, SL; Nobles, CJ; Perkins, NJ; Schisterman, EF; Silver, RM; Sjaarda, L, 2020)
"Hemorrhagic stroke is the most common type of obstetric stroke."2.72Stroke in Pregnancy: A Multidisciplinary Approach. ( Camargo, EC; Singhal, AB, 2021)
"Pregnancy-induced hypertension is a major cause of maternal and fetal morbidity and mortality."2.61Hypertension and Pregnancy: Management and Future Risks. ( Jim, B; Reddy, S, 2019)
" Avoidance of nephrotoxic and teratogenic medications is necessary, and renal dosing of commonly used medications must also be considered."2.61Chronic Kidney Disease and Pregnancy. ( Hladunewich, MA; Hui, D, 2019)
"Documentation of preeclampsia risk factors: multifetal gestation, pregestational diabetes, chronic hypertension (high-risk factors) and nulliparity, a body mass index greater than 30, African American race, a maternal age 35 years or older, an interval of more than 10-years since last birth, and having low socioeconomic status (moderate risk factors)."1.72Estimated Prevalence of Risk Factors for Preeclampsia Among Individuals Giving Birth in the US in 2019. ( Myers, ER; Myers, SO; Swamy, GK; Wheeler, SM, 2022)
"Preeclampsia is a hypertensive disease unique to pregnancy and has a significant impact on maternal and neonatal morbidity and mortality."1.72Assessment of adherence to aspirin for preeclampsia prophylaxis and reasons for nonadherence. ( Olson, DN; Ranzini, AC; Russell, T, 2022)
"Analyze secular trends of preeclampsia in Norway based on risk factors."1.72Substantial decrease in preeclampsia prevalence and risk over two decades: A population-based study of 1,153,227 deliveries in Norway. ( Laine, K; Räisänen, S; Sole, KB; Staff, AC, 2022)
"Aspirin has been shown to be effective in decreasing the risk of preterm preeclampsia; however, there is no consensus on the target population for aspirin prophylaxis."1.56Gottesfeld-Hohler Memorial Foundation Risk Assessment for Early-Onset Preeclampsia in the United States: Think Tank Summary. ( Afshar, Y; Bromley, B; Caughey, AB; Chescheir, N; Copel, JA; Grechukhina, O; Grobman, W; Han, CS; Hobbins, JC; Mallampati, D; Nicolaides, K; Pettker, C; Platt, LD; Saade, G; Sibai, B; Simhan, H; Sonek, J; Werner, E, 2020)

Research

Studies (62)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (3.23)29.6817
2010's32 (51.61)24.3611
2020's28 (45.16)2.80

Authors

AuthorsStudies
Wheeler, SM1
Myers, SO1
Swamy, GK1
Myers, ER1
Sole, KB1
Staff, AC1
Räisänen, S1
Laine, K1
Olson, DN1
Russell, T1
Ranzini, AC1
Pathiraja, PDM1
Alrub, NA1
Sunanda, G1
Liu, YH1
Zhang, YS1
Chen, JY1
Wang, ZJ1
Liu, YX1
Li, JQ1
Xu, XJ1
Xie, NJ1
Lye, S1
Tan, N1
Duan, CY1
Wei, YX1
He, PC1
D'Antonio, F3
Khalil, A3
Rizzo, G3
Fichera, A3
Herrera, M3
Buca, D3
Morelli, R3
Cerra, C3
Orabona, R3
Acuti Martellucci, C3
Flacco, ME3
Prefumo, F3
Bruno, AM1
Allshouse, AA1
Metz, TD1
Theilen, LH2
Kou, X1
Yang, J1
Honigberg, MC1
Truong, B1
Khan, RR1
Xiao, B1
Bhatta, L1
Vy, HMT1
Guerrero, RF1
Schuermans, A1
Selvaraj, MS1
Patel, AP1
Koyama, S1
Cho, SMJ1
Vellarikkal, SK1
Trinder, M1
Urbut, SM1
Gray, KJ1
Brumpton, BM1
Patil, S1
Zöllner, S1
Antopia, MC1
Saxena, R1
Nadkarni, GN1
Do, R1
Yan, Q1
Pe'er, I1
Verma, SS1
Gupta, RM1
Haas, DM1
Martin, HC1
van Heel, DA1
Laisk, T1
Natarajan, P1
Bangi, EF1
Yousuf, MH1
Upadhyay, S1
Jain, P1
Jain, R1
Kavi, A2
Hoffman, MK2
Somannavar, MS1
Metgud, MC1
Goudar, SS2
Moore, J2
Nielsen, E1
Goco, N2
McClure, EM2
Lokangaka, A2
Tshefu, A2
Bauserman, M2
Mwenechanya, M1
Chomba, E2
Carlo, WA2
Figueroa, L2
Krebs, NF2
Jessani, S2
Saleem, S2
Goldenberg, RL2
Das, P2
Patel, A1
Hibberd, PL2
Esamai, F2
Bucher, S2
Koso-Thomas, M1
Silver, R1
Derman, RJ2
Nuss, EE1
Metgud, M1
Somannavar, M1
Okitawutshu, J1
Tembo, AM1
Kurhe, K1
Achieng, E1
Nyongesa, P1
Liechty, EA1
Hemingway-Foday, J1
Silver, RM3
Chen, WY1
Sun, SF1
Zhu, J1
Chen, C1
Lu, D1
Zhang, J2
Jing, S1
Xie, H1
Copel, JA1
Platt, LD1
Hobbins, JC1
Afshar, Y1
Grechukhina, O1
Mallampati, D1
Bromley, B1
Caughey, AB2
Grobman, W1
Han, CS1
Nicolaides, K1
Pettker, C1
Saade, G1
Sibai, B1
Simhan, H1
Sonek, J1
Werner, E1
Chescheir, N1
Bij de Weg, JM2
Abheiden, CNH3
Fuijkschot, WW3
Harmsze, AM2
de Boer, MA5
Thijs, A3
de Vries, JIP3
Ekawati, FM1
Emilia, O1
Brennecke, S1
Gunn, J1
Licqurish, S1
Lau, P1
Campbell, HD1
Mumford, SL2
Purdue-Smithe, AC1
Sjaarda, LA1
Perkins, NJ2
Radoc, JG1
Schisterman, EF2
Ghazanfarpour, M1
Sathyapalan, T1
Banach, M1
Jamialahmadi, T1
Sahebkar, A1
Ramlakhan, KP1
Johnson, MR1
Roos-Hesselink, JW1
de Groot, C1
Gibson, KS1
Hameed, AB1
Nobles, CJ1
Mendola, P1
Kim, K1
Andriessen, VC1
Connell, M1
Sjaarda, L1
Scott, G1
Gillon, TE1
Pels, A1
von Dadelszen, P2
Magee, LA2
Lanssens, D1
Thijs, IM1
Gyselaers, W1
Booker, WA1
He, G2
Chen, Y1
Chen, M1
Liu, X1
Camargo, EC1
Singhal, AB1
Xiang, X1
Wang, F1
Zhao, N1
Zhou, Z1
Jackson, JR1
Gregg, AR1
Iriye, BK1
Gregory, KD1
Saade, GR1
Grobman, WA1
Brown, HL1
Lin, CY1
Broström, A1
Nilsen, P1
Pakpour, AH1
Chahine, KM1
Sibai, BM1
Miller, EC1
Boehme, AK1
Chung, NT1
Wang, SS1
Lacey, JV1
Lakshminarayan, K1
Zhong, C1
Woo, D1
Bello, NA1
Wapner, R1
Elkind, MSV1
Willey, JZ1
Feske, SK1
Bushnell, C2
Leavitt, K1
Običan, S1
Yankowitz, J1
Reddy, S1
Jim, B1
Vestering, A1
Bekker, MN1
Grobbee, DE1
van der Graaf, R1
Franx, A1
Crombag, NMT1
Browne, JL1
Hui, D1
Hladunewich, MA1
Groeneveld, E2
Lambers, MJ2
Lambalk, CB2
Broeze, KA1
Haapsamo, M2
de Sutter, P1
Schoot, BC1
Schats, R2
Mol, BW1
Hompes, PG2
Vigil-De Gracia, P1
Dominguez, L1
Solis, A1
van Hoorn, ME1
Hague, WM1
van Pampus, MG1
Bezemer, D1
de Vries, JI3
Shinozaki, N1
Ebina, Y1
Deguchi, M1
Tanimura, K1
Morizane, M1
Yamada, H1
Bartsch, E1
Medcalf, KE1
Park, AL1
Ray, JG1
Helou, A1
Walker, S1
Stewart, K1
George, J1
Abheiden, CN2
Blomjous, BS1
Kroese, SJ1
Bultink, IE1
Fritsch-Stork, RD1
Lely, AT1
van Reuler, AV1
Liu, FM1
Zhao, M1
Wang, M1
Yang, HL1
Li, L1
Arduç, A1
van Diemen, JJK1
Hoozemans, DA1
Homburg, R1
Martikainen, H1
Tinkanen, H1
Heinonen, S1
Nuojua-Huttunen, S1
Räsänen, J1
Graham, DF1
Hadlow, N1
Tsokos, N1
Oates, R1
Ismail, SK1
Higgins, JR1
Morales-Vidal, S1
Schneck, MJ1
Flaster, MS1
Biller, J1
Tate, J1
Bujold, E1
Pasquier, JC1
Bakhti, A1
Vaiman, D1
Ames, M1
Rueda, J1
Vainio, M1
Riutta, A1
Koivisto, AM1
Mäenpää, J1

Clinical Trials (13)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
The Effects of Aspirin in Gestation and Reproduction: A Multi-center, Controlled, Double-blind Randomized Trial.[NCT00467363]1,228 participants (Actual)Interventional2007-06-30Completed
PREMOM II: Pregnancy Remote Monitoring of Women With Gestational Hypertensive Disorders[NCT04031430]6,107 participants (Anticipated)Interventional2019-06-18Recruiting
STUDY PROTOCOL FOR A PROSPECTIVE, MULTICENTRE, COHORT STUDY: Preeclampsia Sequential Screening Using Angiogenic Factors During First Trimester of Pregnancy (CRISP STUDY)[NCT04767438]6,560 participants (Anticipated)Observational2021-03-31Not yet recruiting
A Pragmatic Randomized Study Comparing 81 mg Aspirin Versus 162 mg Aspirin in the Prevention of Preeclampsia During Pregnancy[NCT04158830]Phase 40 participants (Actual)Interventional2020-06-01Withdrawn (stopped due to PI is no longer at this University.)
162 mg of Aspirin for Prevention of Preeclampsia[NCT05221164]Phase 4200 participants (Anticipated)Interventional2021-07-06Recruiting
Best Practice Alert (BPA) for Low Dose Aspirin Recommendation in High-risk Pregnancies: a Randomized Controlled Trial[NCT05802940]640 participants (Anticipated)Interventional2023-06-19Not yet recruiting
Aspirin for the Prevention of Preeclampsia in Women With Stage 1 Hypertension: A Pilot Study[NCT04908982]Phase 460 participants (Anticipated)Interventional2021-05-28Recruiting
Prevention of Preeclampsia With Aspirin Administered From the Beginning of Pregnancy in Recipients of Donated Oocytes.[NCT02174328]Phase 381 participants (Actual)Interventional2014-05-21Terminated (stopped due to Halted prematurely due to low recruitment rate.)
Prevention of Pre-eclampsia Using Metformin: a Randomized Control Trial[NCT04855513]414 participants (Anticipated)Interventional2022-03-24Not yet recruiting
Assessment of the Cardiovascular Risk Profile of Infants Exposed to Pre-eclampsia in Utero[NCT05091827]234 participants (Anticipated)Observational2021-11-30Not yet recruiting
A Randomized Controlled Trial Comparing Low Doses Of Aspirin In The Prevention Of Preeclampsia (ASAPP)[NCT04070573]Phase 3400 participants (Anticipated)Interventional2019-10-21Enrolling by invitation
The Significance of Low-Dose Aspirin on Ovarian Responsiveness, Uterine Hemodynamics and Pregnancy Outcome in in Vitro Fertilization and in Intracytoplasmic Sperm Injection: A Randomized, Placebo-Controlled Double-Blind Study[NCT00683202]374 participants (Actual)Interventional2001-03-31Completed
Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)[NCT02409680]11,976 participants (Actual)Interventional2016-03-23Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Abruption

Partial or complete abruption (ie, premature separation of the placenta) (NCT00467363)
Timeframe: until delivery

Interventionparticipants (Number)
Aspirin7
Placebo5

Clinically Recognized Pregnancy

(NCT00467363)
Timeframe: 8-weeks

Interventionpregnancy (Number)
Aspirin374
Placebo346

Early Pregnancy Loss (EPL)

Implantation failures (NCT00467363)
Timeframe: 8 weeks

Interventionpregnancy (Number)
Aspirin28
Placebo27

Ectopic Pregnancy

(NCT00467363)
Timeframe: within 6 weeks

Interventionpregnancy (Number)
Aspirin3
Placebo3

Fetal Pregnancy Loss

(NCT00467363)
Timeframe: until 40 weeks

Interventionpregnancy (Number)
Aspirin4
Placebo6

hCG Recognized Pregnancy

(NCT00467363)
Timeframe: within 8-weeks of gestation

Interventionpregnancy (Number)
Aspirin394
Placebo363

Live Birth

Live birth was obtained prospectively by maternal report and abstraction from medical records by trained staff . (NCT00467363)
Timeframe: after delivery

Interventionlivebirths (Number)
Aspirin309
Placebo286

Molar Pregnancy

(NCT00467363)
Timeframe: 8 weeks

Interventionpregnancy (Number)
Aspirin0
Placebo0

Preeclampsia

(NCT00467363)
Timeframe: until delivery

Interventionparticipants (Number)
Aspirin32
Placebo30

Pregnancy Losses Occurring Less Than 10 Weeks

Includes preembryonic and embryonic losses (exclusive of implantation failures) (NCT00467363)
Timeframe: less than 10-weeks

Interventionpregnancy (Number)
Aspirin56
Placebo53

Preterm Birth

(NCT00467363)
Timeframe: until delivery

Interventioninfants (Number)
Aspirin22
Placebo31

Small for Gestational Age Infant

birthweight (NCT00467363)
Timeframe: until delivery

Interventiongrams (Mean)
Aspirin3327
Placebo3315

Stillbirth

(NCT00467363)
Timeframe: 40 weeks

Interventionparticipants (Number)
Aspirin2
Placebo2

Fetal Outcome 1 - Incidence of Early Preterm Delivery (<34 Weeks)

- Early preterm delivery (<34 weeks) (NCT02409680)
Timeframe: At delivery

InterventionParticipants (Count of Participants)
Intervention Arm189
Placebo Arm230

Fetal Outcome 2 - Incidence of Actual Birth Weight <2500g

- Birth weight <2500g (NCT02409680)
Timeframe: At delivery

InterventionParticipants (Count of Participants)
Intervention Arm1078
Placebo Arm1153

Fetal Outcome 3 - Incidence of Actual Birth Weight <1500g

- Birth weight <1500g (NCT02409680)
Timeframe: At delivery

InterventionParticipants (Count of Participants)
Intervention Arm78
Placebo Arm101

Fetal Outcome 4 - Incidence of Fetal Loss

- Incidence of Fetal Loss (NCT02409680)
Timeframe: At delivery

InterventionParticipants (Count of Participants)
Intervention Arm303
Placebo Arm353

Fetal Outcome 5 - Incidence of Spontaneous Abortion

- Incidence of Spontaneous Abortion (NCT02409680)
Timeframe: At delivery

InterventionParticipants (Count of Participants)
Intervention Arm134
Placebo Arm152

Fetal Outcome 6 - Incidence of All Stillbirth

- Incidence of All stillbirth (NCT02409680)
Timeframe: At delivery

InterventionParticipants (Count of Participants)
Intervention Arm141
Placebo Arm166

Fetal Outcome 7 - Incidence of Medical Termination of Pregnancy

- Incidence of Medical Termination of Pregnancy (NCT02409680)
Timeframe: At delivery

InterventionParticipants (Count of Participants)
Intervention Arm42
Placebo Arm30

Incidence of Hypertensive Disorders of Pregnancy

- Hypertensive disorders of pregnancy is defined by the characterization of evidence of a hypertensive disorder, including either preeclampsia or eclampsia occurring during the pregnancy. (NCT02409680)
Timeframe: Evidence of hypertensive disorder during the pregnancy (prior to delivery/birth)

InterventionParticipants (Count of Participants)
Intervention Arm352
Placebo Arm325

Incidence of Perinatal Mortality

- Incidence of Perinatal Mortality (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery

InterventionParticipants (Count of Participants)
Intervention Arm264
Placebo Arm309

Incidence of Preterm Birth

The primary outcome of this study is incidence of preterm birth, which will be defined as delivery at or after 20 0/7 weeks and prior to 37 0/7 weeks. This will be determined based on actual date of delivery in comparison to the projected estimated due date (EDD), independent of whether or not the preterm delivery is indicated or spontaneous. (NCT02409680)
Timeframe: At delivery

InterventionParticipants (Count of Participants)
Intervention Arm668
Placebo Arm754

Incidence of Small for Gestational Age (SGA)

- Small for gestational age (SGA) as defined by the INTERGROWTH-21st standard (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery

InterventionParticipants (Count of Participants)
Intervention Arm1506
Placebo Arm1564

Maternal Outcome 1 - Incidence of Vaginal Bleeding

- Vaginal bleeding (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery

InterventionParticipants (Count of Participants)
Intervention Arm214
Placebo Arm246

Maternal Outcome 2 - Incidence of Antepartum Hemorrhage

- Antepartum hemorrhage (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery

InterventionParticipants (Count of Participants)
Intervention Arm26
Placebo Arm25

Maternal Outcome 3 - Incidence of Postpartum Hemorrhage

- Postpartum hemorrhage (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery

InterventionParticipants (Count of Participants)
Intervention Arm54
Placebo Arm43

Maternal Outcome 4 - Incidence of Maternal Mortality

- Incidence of Maternal Mortality (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery

InterventionParticipants (Count of Participants)
Intervention Arm9
Placebo Arm12

Maternal Outcome 5 - Incidence of Late Abortion

- Incidence of Late Abortion (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery

InterventionParticipants (Count of Participants)
Intervention Arm23
Placebo Arm30

Maternal Outcome 6 - Change in Maternal Hemoglobin

Hemoglobin < 7.0 gm/dl at 26-30 weeks gestation or a drop of 3.5+ gm/dl from screening to 26-30 weeks gestation (NCT02409680)
Timeframe: At enrollment, 4 weeks post enrollment, and 26-30 weeks GA.

InterventionParticipants (Count of Participants)
Intervention Arm290
Placebo Arm333

Maternal Outcome 7 - Incidence of Preterm, Preeclampsia

Early preterm delivery (<34 weeks) and hypertensive disorders (i.e.: preeclampsia) (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery

InterventionParticipants (Count of Participants)
Intervention Arm8
Placebo Arm21

Reviews

21 reviews available for aspirin and Gestational Hypertension

ArticleYear
Comparative effectiveness of prophylactic strategies for preeclampsia: a network meta-analysis of randomized controlled trials.
    American journal of obstetrics and gynecology, 2023, Volume: 228, Issue:5

    Topics: Aspirin; Bayes Theorem; Calcium; Female; Heparin, Low-Molecular-Weight; Humans; Hypertension, Pregna

2023
Aspirin for prevention of preeclampsia and adverse perinatal outcome in twin pregnancies: a systematic review and meta-analysis.
    American journal of obstetrics & gynecology MFM, 2023, Volume: 5, Issue:2

    Topics: Aspirin; Birth Weight; Female; Fetal Growth Retardation; Humans; Hypertension, Pregnancy-Induced; In

2023
Aspirin for prevention of preeclampsia and adverse perinatal outcome in twin pregnancies: a systematic review and meta-analysis.
    American journal of obstetrics & gynecology MFM, 2023, Volume: 5, Issue:2

    Topics: Aspirin; Birth Weight; Female; Fetal Growth Retardation; Humans; Hypertension, Pregnancy-Induced; In

2023
Aspirin for prevention of preeclampsia and adverse perinatal outcome in twin pregnancies: a systematic review and meta-analysis.
    American journal of obstetrics & gynecology MFM, 2023, Volume: 5, Issue:2

    Topics: Aspirin; Birth Weight; Female; Fetal Growth Retardation; Humans; Hypertension, Pregnancy-Induced; In

2023
Aspirin for prevention of preeclampsia and adverse perinatal outcome in twin pregnancies: a systematic review and meta-analysis.
    American journal of obstetrics & gynecology MFM, 2023, Volume: 5, Issue:2

    Topics: Aspirin; Birth Weight; Female; Fetal Growth Retardation; Humans; Hypertension, Pregnancy-Induced; In

2023
Aspirin for prevention of preeclampsia and adverse perinatal outcome in twin pregnancies: a systematic review and meta-analysis.
    American journal of obstetrics & gynecology MFM, 2023, Volume: 5, Issue:2

    Topics: Aspirin; Birth Weight; Female; Fetal Growth Retardation; Humans; Hypertension, Pregnancy-Induced; In

2023
Aspirin for prevention of preeclampsia and adverse perinatal outcome in twin pregnancies: a systematic review and meta-analysis.
    American journal of obstetrics & gynecology MFM, 2023, Volume: 5, Issue:2

    Topics: Aspirin; Birth Weight; Female; Fetal Growth Retardation; Humans; Hypertension, Pregnancy-Induced; In

2023
Aspirin for prevention of preeclampsia and adverse perinatal outcome in twin pregnancies: a systematic review and meta-analysis.
    American journal of obstetrics & gynecology MFM, 2023, Volume: 5, Issue:2

    Topics: Aspirin; Birth Weight; Female; Fetal Growth Retardation; Humans; Hypertension, Pregnancy-Induced; In

2023
Aspirin for prevention of preeclampsia and adverse perinatal outcome in twin pregnancies: a systematic review and meta-analysis.
    American journal of obstetrics & gynecology MFM, 2023, Volume: 5, Issue:2

    Topics: Aspirin; Birth Weight; Female; Fetal Growth Retardation; Humans; Hypertension, Pregnancy-Induced; In

2023
Aspirin for prevention of preeclampsia and adverse perinatal outcome in twin pregnancies: a systematic review and meta-analysis.
    American journal of obstetrics & gynecology MFM, 2023, Volume: 5, Issue:2

    Topics: Aspirin; Birth Weight; Female; Fetal Growth Retardation; Humans; Hypertension, Pregnancy-Induced; In

2023
Polygenic prediction of preeclampsia and gestational hypertension.
    Nature medicine, 2023, Volume: 29, Issue:6

    Topics: Aspirin; Child; Eclampsia; Female; Humans; Hypertension; Hypertension, Pregnancy-Induced; Pre-Eclamp

2023
Comprehensive Review of Hypertensive Disorders Related to Pregnancy.
    Southern medical journal, 2023, Volume: 116, Issue:6

    Topics: Aspirin; Eclampsia; Female; Humans; Hypertension, Pregnancy-Induced; Infant, Newborn; Placenta; Pre-

2023
Clinical efficacy of low-dose aspirin combined with calcium in preventing preeclampsia: A systematic review and meta-analysis.
    Medicine, 2023, Aug-25, Volume: 102, Issue:34

    Topics: Aspirin; Calcium; Calcium, Dietary; Female; Humans; Hypertension, Pregnancy-Induced; Infant, Newborn

2023
Opportunities for improving hypertensive disorders of pregnancy (HDP) management in primary care settings: A review of international published guidelines in the context of pregnancy care in Indonesia.
    Pregnancy hypertension, 2020, Volume: 19

    Topics: Aspirin; Calcium; Calcium-Regulating Hormones and Agents; Communication; Female; General Practice; H

2020
Prophylactic aspirin for preventing pre-eclampsia and its complications: An overview of meta-analyses.
    Drug discovery today, 2020, Volume: 25, Issue:8

    Topics: Abruptio Placentae; Aspirin; Female; Fetal Growth Retardation; Hemorrhage; Humans; Hypertension, Pre

2020
Pregnancy and cardiovascular disease.
    Nature reviews. Cardiology, 2020, Volume: 17, Issue:11

    Topics: Acute Coronary Syndrome; Antihypertensive Agents; Aortic Dissection; Arrhythmias, Cardiac; Aspirin;

2020
Guidelines-similarities and dissimilarities: a systematic review of international clinical practice guidelines for pregnancy hypertension.
    American journal of obstetrics and gynecology, 2022, Volume: 226, Issue:2S

    Topics: Anticonvulsants; Antihypertensive Agents; Aspirin; Calcium; Delivery, Obstetric; Female; Glucocortic

2022
Hypertensive Disorders of Pregnancy.
    Clinics in perinatology, 2020, Volume: 47, Issue:4

    Topics: Anticonvulsants; Antihypertensive Agents; Aspirin; Chronic Disease; Delivery, Obstetric; Eclampsia;

2020
Stroke in Pregnancy: A Multidisciplinary Approach.
    Obstetrics and gynecology clinics of North America, 2021, Volume: 48, Issue:1

    Topics: Aspirin; Brain Diseases; Cardiomyopathies; Cesarean Section; Eclampsia; Embolism, Paradoxical; Femal

2021
Updates on the Recognition, Prevention and Management of Hypertension in Pregnancy.
    Obstetrics and gynecology clinics of North America, 2017, Volume: 44, Issue:2

    Topics: Aspirin; Female; Humans; Hypertension, Pregnancy-Induced; Platelet Aggregation Inhibitors; Pregnancy

2017
Treatment and Prevention of Hypertensive Disorders During Pregnancy.
    Clinics in perinatology, 2019, Volume: 46, Issue:2

    Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Aspirin; Calcium Channel Blockers; Chronic Dis

2019
Hypertension and Pregnancy: Management and Future Risks.
    Advances in chronic kidney disease, 2019, Volume: 26, Issue:2

    Topics: Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Chronic Disease; Diuretics; Female; Human

2019
Chronic Kidney Disease and Pregnancy.
    Obstetrics and gynecology, 2019, Volume: 133, Issue:6

    Topics: Aspirin; Female; Glomerular Filtration Rate; Humans; Hypertension, Pregnancy-Induced; Infant, Newbor

2019
Preconceptional low-dose aspirin for the prevention of hypertensive pregnancy complications and preterm delivery after IVF: a meta-analysis with individual patient data.
    Human reproduction (Oxford, England), 2013, Volume: 28, Issue:6

    Topics: Adult; Aspirin; Female; Fertilization in Vitro; Humans; Hypertension, Pregnancy-Induced; Logistic Mo

2013
Clinical risk factors for pre-eclampsia determined in early pregnancy: systematic review and meta-analysis of large cohort studies.
    BMJ (Clinical research ed.), 2016, Apr-19, Volume: 353

    Topics: Aspirin; Body Mass Index; Chronic Disease; Cohort Studies; Early Diagnosis; Female; Humans; Hyperten

2016
Clinical risk factors for pre-eclampsia determined in early pregnancy: systematic review and meta-analysis of large cohort studies.
    BMJ (Clinical research ed.), 2016, Apr-19, Volume: 353

    Topics: Aspirin; Body Mass Index; Chronic Disease; Cohort Studies; Early Diagnosis; Female; Humans; Hyperten

2016
Clinical risk factors for pre-eclampsia determined in early pregnancy: systematic review and meta-analysis of large cohort studies.
    BMJ (Clinical research ed.), 2016, Apr-19, Volume: 353

    Topics: Aspirin; Body Mass Index; Chronic Disease; Cohort Studies; Early Diagnosis; Female; Humans; Hyperten

2016
Clinical risk factors for pre-eclampsia determined in early pregnancy: systematic review and meta-analysis of large cohort studies.
    BMJ (Clinical research ed.), 2016, Apr-19, Volume: 353

    Topics: Aspirin; Body Mass Index; Chronic Disease; Cohort Studies; Early Diagnosis; Female; Humans; Hyperten

2016
Preventing deaths due to the hypertensive disorders of pregnancy.
    Best practice & research. Clinical obstetrics & gynaecology, 2016, Volume: 36

    Topics: Aspirin; Birth Intervals; Calcium; Cardiotocography; Dietary Supplements; Eclampsia; Female; Food Su

2016
Hemostasis in pre-eclampsia.
    Seminars in thrombosis and hemostasis, 2011, Volume: 37, Issue:2

    Topics: Aspirin; Female; Hemostasis; Heparin, Low-Molecular-Weight; Humans; Hypertension, Pregnancy-Induced;

2011
Pregnancy and stroke risk in women.
    Women's health (London, England), 2011, Volume: 7, Issue:3

    Topics: Aspirin; Brain Ischemia; Female; Fibrinolytic Agents; Humans; Hypertension, Pregnancy-Induced; Plate

2011
Ambulatory management of chronic hypertension in pregnancy.
    Clinical obstetrics and gynecology, 2012, Volume: 55, Issue:3

    Topics: Ambulatory Care; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Aspirin; Disease

2012

Trials

12 trials available for aspirin and Gestational Hypertension

ArticleYear
Labetalol, Low-dose Aspirin, and Vitamin E and Calcium for Gestational Hypertension and Influence on MicroRNA-126 and PLGF Levels.
    Alternative therapies in health and medicine, 2023, Volume: 29, Issue:4

    Topics: Aspirin; Calcium; Female; Humans; Hypertension; Hypertension, Pregnancy-Induced; Labetalol; MicroRNA

2023
Aspirin delays the onset of hypertensive disorders of pregnancy among nulliparous pregnant women: A secondary analysis of the ASPIRIN trial.
    BJOG : an international journal of obstetrics and gynaecology, 2023, Volume: 130 Suppl 3

    Topics: Aspirin; Child; Child Health; Female; Fetal Growth Retardation; Humans; Hypertension, Pregnancy-Indu

2023
The impact of risk factors on aspirin's efficacy for the prevention of preterm birth.
    American journal of obstetrics & gynecology MFM, 2023, Volume: 5, Issue:10

    Topics: Aspirin; Female; Humans; Hypertension, Pregnancy-Induced; Infant, Newborn; Male; Perinatal Death; Pr

2023
Preconception Blood Pressure and Its Change Into Early Pregnancy: Early Risk Factors for Preeclampsia and Gestational Hypertension.
    Hypertension (Dallas, Tex. : 1979), 2020, Volume: 76, Issue:3

    Topics: Adult; Aspirin; Blood Pressure Determination; Drug Monitoring; Early Diagnosis; Female; Humans; Hype

2020
Design of the Pregnancy REmote MOnitoring II study (PREMOM II): a multicenter, randomized controlled trial of remote monitoring for gestational hypertensive disorders.
    BMC pregnancy and childbirth, 2020, Oct-15, Volume: 20, Issue:1

    Topics: Adult; Aspirin; Cost-Benefit Analysis; Female; Follow-Up Studies; Humans; Hypertension, Pregnancy-In

2020
Treatment of pregnancy-induced hypertension compared with labetalol, low dose aspirin and placebo.
    Cellular and molecular biology (Noisy-le-Grand, France), 2020, Dec-31, Volume: 66, Issue:8

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Aspirin; Blood Pressure; Do

2020
Management of chronic hypertension during pregnancy with furosemide, amlodipine or aspirin: a pilot clinical trial.
    The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians, 2014, Volume: 27, Issue:13

    Topics: Adult; Amlodipine; Antihypertensive Agents; Aspirin; Diuretics; Female; Furosemide; Humans; Hyperten

2014
Low-molecular-weight heparin and aspirin in the prevention of recurrent early-onset pre-eclampsia in women with antiphospholipid antibodies: the FRUIT-RCT.
    European journal of obstetrics, gynecology, and reproductive biology, 2016, Volume: 197

    Topics: Adult; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Aspirin; Australia; Drug Therapy, Co

2016
Effect of regular oral intake of aspirin during pregnancy on pregnancy outcome of high-risk pregnancy-induced hypertension syndrome patients.
    European review for medical and pharmacological sciences, 2016, Volume: 20, Issue:23

    Topics: Aspirin; Female; Humans; Hypertension; Hypertension, Pregnancy-Induced; Pre-Eclampsia; Pregnancy; Pr

2016
Lower incidence of hypertensive complications during pregnancy in patients treated with low-dose aspirin during in vitro fertilization and early pregnancy.
    Human reproduction (Oxford, England), 2009, Volume: 24, Issue:10

    Topics: Adult; Aspirin; Double-Blind Method; Female; Fertilization in Vitro; Humans; Hypertension, Pregnancy

2009
Low-dose aspirin therapy and hypertensive pregnancy complications in unselected IVF and ICSI patients: a randomized, placebo-controlled, double-blind study.
    Human reproduction (Oxford, England), 2010, Volume: 25, Issue:12

    Topics: Adult; Aspirin; Double-Blind Method; Female; Fertilization in Vitro; Humans; Hypertension, Pregnancy

2010
Prostacyclin, thromboxane A and the effect of low-dose ASA in pregnancies at high risk for hypertensive disorders.
    Acta obstetricia et gynecologica Scandinavica, 2004, Volume: 83, Issue:12

    Topics: 6-Ketoprostaglandin F1 alpha; Aspirin; Cyclooxygenase Inhibitors; Epoprostenol; Female; Humans; Hype

2004
Prostacyclin, thromboxane A and the effect of low-dose ASA in pregnancies at high risk for hypertensive disorders.
    Acta obstetricia et gynecologica Scandinavica, 2004, Volume: 83, Issue:12

    Topics: 6-Ketoprostaglandin F1 alpha; Aspirin; Cyclooxygenase Inhibitors; Epoprostenol; Female; Humans; Hype

2004
Prostacyclin, thromboxane A and the effect of low-dose ASA in pregnancies at high risk for hypertensive disorders.
    Acta obstetricia et gynecologica Scandinavica, 2004, Volume: 83, Issue:12

    Topics: 6-Ketoprostaglandin F1 alpha; Aspirin; Cyclooxygenase Inhibitors; Epoprostenol; Female; Humans; Hype

2004
Prostacyclin, thromboxane A and the effect of low-dose ASA in pregnancies at high risk for hypertensive disorders.
    Acta obstetricia et gynecologica Scandinavica, 2004, Volume: 83, Issue:12

    Topics: 6-Ketoprostaglandin F1 alpha; Aspirin; Cyclooxygenase Inhibitors; Epoprostenol; Female; Humans; Hype

2004

Other Studies

29 other studies available for aspirin and Gestational Hypertension

ArticleYear
Estimated Prevalence of Risk Factors for Preeclampsia Among Individuals Giving Birth in the US in 2019.
    JAMA network open, 2022, 01-04, Volume: 5, Issue:1

    Topics: Adult; Aspirin; Female; Humans; Hypertension, Pregnancy-Induced; Pre-Eclampsia; Pregnancy; Prevalenc

2022
Substantial decrease in preeclampsia prevalence and risk over two decades: A population-based study of 1,153,227 deliveries in Norway.
    Pregnancy hypertension, 2022, Volume: 28

    Topics: Aspirin; Cohort Studies; Female; Humans; Hypertension, Pregnancy-Induced; Pre-Eclampsia; Pregnancy;

2022
Assessment of adherence to aspirin for preeclampsia prophylaxis and reasons for nonadherence.
    American journal of obstetrics & gynecology MFM, 2022, Volume: 4, Issue:5

    Topics: Aspirin; Autoimmune Diseases; Female; Humans; Hypertension, Pregnancy-Induced; Infant, Newborn; Pre-

2022
Indications for commencing aspirin for the prevention of pregnancy-induced hypertension and pre-eclampsia spectrum disorders.
    Australian journal of general practice, 2022, Volume: 51, Issue:10

    Topics: Aspirin; Female; Humans; Hypertension, Pregnancy-Induced; Pre-Eclampsia; Pregnancy

2022
Hypertensive disorders of pregnancy pre- and postaspirin guideline publication in individuals with pregestational diabetes mellitus.
    American journal of obstetrics & gynecology MFM, 2023, Volume: 5, Issue:4

    Topics: Aspirin; Cross-Sectional Studies; Diabetes Mellitus; Female; Humans; Hypertension, Pregnancy-Induced

2023
Aspirin use during pregnancy and hypertensive disorders in women with various risks.
    Pregnancy hypertension, 2019, Volume: 17

    Topics: Adult; Aspirin; China; Cohort Studies; Female; Humans; Hypertension, Pregnancy-Induced; Platelet Agg

2019
Gottesfeld-Hohler Memorial Foundation Risk Assessment for Early-Onset Preeclampsia in the United States: Think Tank Summary.
    Obstetrics and gynecology, 2020, Volume: 135, Issue:1

    Topics: Aspirin; Consensus; Cost-Benefit Analysis; Female; Gestational Age; Humans; Hypertension, Pregnancy-

2020
Resistance of aspirin during and after pregnancy: A longitudinal cohort study.
    Pregnancy hypertension, 2020, Volume: 19

    Topics: Adult; Aspirin; Cohort Studies; Drug Resistance; Female; Humans; Hypertension, Pregnancy-Induced; Lo

2020
Platelet activation and placenta-mediated adverse pregnancy outcomes: an ancillary study to the Effects of Aspirin in Gestation and Reproduction trial.
    American journal of obstetrics and gynecology, 2020, Volume: 223, Issue:5

    Topics: Abruptio Placentae; Adult; Aspirin; Female; Fetal Growth Retardation; Humans; Hypertension, Pregnanc

2020
Patients' perspective on aspirin during pregnancy: a survey.
    Hypertension in pregnancy, 2020, Volume: 39, Issue:4

    Topics: Adult; Aspirin; Female; Health Knowledge, Attitudes, Practice; Humans; Hypertension, Pregnancy-Induc

2020
Society for Maternal-Fetal Medicine Special Statement: Checklist for postpartum discharge of women with hypertensive disorders.
    American journal of obstetrics and gynecology, 2020, Volume: 223, Issue:4

    Topics: Aspirin; Blood Pressure Monitoring, Ambulatory; Checklist; Exercise; Female; Humans; Hypertension, P

2020
Efficacy and safety of low dose aspirin and magnesium sulfate in the treatment of pregnancy induced hypertension: A protocol for systematic review and meta-analysis.
    Medicine, 2020, Nov-13, Volume: 99, Issue:46

    Topics: Aspirin; Clinical Protocols; Female; Humans; Hypertension, Pregnancy-Induced; Magnesium Sulfate; Met

2020
Quality measures in high-risk pregnancies: Executive Summary of a Cooperative Workshop of the Society for Maternal-Fetal Medicine, National Institute of Child Health and Human Development, and the American College of Obstetricians and Gynecologists.
    American journal of obstetrics and gynecology, 2017, Volume: 217, Issue:4

    Topics: Antibiotic Prophylaxis; Aspirin; Cesarean Section; Congresses as Topic; Female; Fetal Growth Retarda

2017
Using extended theory of planned behavior to understand aspirin adherence in pregnant women.
    Pregnancy hypertension, 2018, Volume: 12

    Topics: Adaptation, Psychological; Adult; Aspirin; Cardiovascular Agents; Female; Health Knowledge, Attitude

2018
ACOG Committee Opinion No. 743 Summary: Low-Dose Aspirin Use During Pregnancy.
    Obstetrics and gynecology, 2018, Volume: 132, Issue:1

    Topics: Adult; Aspirin; Female; Gestational Age; Humans; Hypertension, Pregnancy-Induced; Platelet Aggregati

2018
ACOG Committee Opinion No. 743: Low-Dose Aspirin Use During Pregnancy.
    Obstetrics and gynecology, 2018, Volume: 132, Issue:1

    Topics: Adult; Aspirin; Female; Gestational Age; Humans; Hypertension, Pregnancy-Induced; Platelet Aggregati

2018
ACOG Committee Opinion No. 743: Low-Dose Aspirin Use During Pregnancy.
    Obstetrics and gynecology, 2018, Volume: 132, Issue:1

    Topics: Adult; Aspirin; Female; Gestational Age; Humans; Hypertension, Pregnancy-Induced; Platelet Aggregati

2018
ACOG Committee Opinion No. 743: Low-Dose Aspirin Use During Pregnancy.
    Obstetrics and gynecology, 2018, Volume: 132, Issue:1

    Topics: Adult; Aspirin; Female; Gestational Age; Humans; Hypertension, Pregnancy-Induced; Platelet Aggregati

2018
ACOG Committee Opinion No. 743: Low-Dose Aspirin Use During Pregnancy.
    Obstetrics and gynecology, 2018, Volume: 132, Issue:1

    Topics: Adult; Aspirin; Female; Gestational Age; Humans; Hypertension, Pregnancy-Induced; Platelet Aggregati

2018
ACOG Committee Opinion No. 743: Low-Dose Aspirin Use During Pregnancy.
    Obstetrics and gynecology, 2018, Volume: 132, Issue:1

    Topics: Adult; Aspirin; Female; Gestational Age; Humans; Hypertension, Pregnancy-Induced; Platelet Aggregati

2018
ACOG Committee Opinion No. 743: Low-Dose Aspirin Use During Pregnancy.
    Obstetrics and gynecology, 2018, Volume: 132, Issue:1

    Topics: Adult; Aspirin; Female; Gestational Age; Humans; Hypertension, Pregnancy-Induced; Platelet Aggregati

2018
ACOG Committee Opinion No. 743: Low-Dose Aspirin Use During Pregnancy.
    Obstetrics and gynecology, 2018, Volume: 132, Issue:1

    Topics: Adult; Aspirin; Female; Gestational Age; Humans; Hypertension, Pregnancy-Induced; Platelet Aggregati

2018
ACOG Committee Opinion No. 743: Low-Dose Aspirin Use During Pregnancy.
    Obstetrics and gynecology, 2018, Volume: 132, Issue:1

    Topics: Adult; Aspirin; Female; Gestational Age; Humans; Hypertension, Pregnancy-Induced; Platelet Aggregati

2018
ACOG Committee Opinion No. 743: Low-Dose Aspirin Use During Pregnancy.
    Obstetrics and gynecology, 2018, Volume: 132, Issue:1

    Topics: Adult; Aspirin; Female; Gestational Age; Humans; Hypertension, Pregnancy-Induced; Platelet Aggregati

2018
ACOG Committee Opinion No. 743: Low-Dose Aspirin Use During Pregnancy.
    Obstetrics and gynecology, 2018, Volume: 132, Issue:1

    Topics: Adult; Aspirin; Female; Gestational Age; Humans; Hypertension, Pregnancy-Induced; Platelet Aggregati

2018
ACOG Committee Opinion No. 743: Low-Dose Aspirin Use During Pregnancy.
    Obstetrics and gynecology, 2018, Volume: 132, Issue:1

    Topics: Adult; Aspirin; Female; Gestational Age; Humans; Hypertension, Pregnancy-Induced; Platelet Aggregati

2018
ACOG Committee Opinion No. 743: Low-Dose Aspirin Use During Pregnancy.
    Obstetrics and gynecology, 2018, Volume: 132, Issue:1

    Topics: Adult; Aspirin; Female; Gestational Age; Humans; Hypertension, Pregnancy-Induced; Platelet Aggregati

2018
ACOG Committee Opinion No. 743: Low-Dose Aspirin Use During Pregnancy.
    Obstetrics and gynecology, 2018, Volume: 132, Issue:1

    Topics: Adult; Aspirin; Female; Gestational Age; Humans; Hypertension, Pregnancy-Induced; Platelet Aggregati

2018
ACOG Committee Opinion No. 743: Low-Dose Aspirin Use During Pregnancy.
    Obstetrics and gynecology, 2018, Volume: 132, Issue:1

    Topics: Adult; Aspirin; Female; Gestational Age; Humans; Hypertension, Pregnancy-Induced; Platelet Aggregati

2018
ACOG Committee Opinion No. 743: Low-Dose Aspirin Use During Pregnancy.
    Obstetrics and gynecology, 2018, Volume: 132, Issue:1

    Topics: Adult; Aspirin; Female; Gestational Age; Humans; Hypertension, Pregnancy-Induced; Platelet Aggregati

2018
ACOG Committee Opinion No. 743: Low-Dose Aspirin Use During Pregnancy.
    Obstetrics and gynecology, 2018, Volume: 132, Issue:1

    Topics: Adult; Aspirin; Female; Gestational Age; Humans; Hypertension, Pregnancy-Induced; Platelet Aggregati

2018
Chronic Hypertension in Pregnancy: New Concepts for Classification and Management.
    American journal of perinatology, 2019, Volume: 36, Issue:2

    Topics: Adult; Antihypertensive Agents; Aspirin; Chronic Disease; Female; Humans; Hypertension; Hypertension

2019
Aspirin reduces long-term stroke risk in women with prior hypertensive disorders of pregnancy.
    Neurology, 2019, 01-22, Volume: 92, Issue:4

    Topics: Adult; Age Factors; Aspirin; Female; Fibrinolytic Agents; Follow-Up Studies; Hospitalists; Humans; H

2019
Stroke prevention: How low can you go?
    Neurology, 2019, 01-22, Volume: 92, Issue:4

    Topics: Aspirin; Female; Humans; Hypertension, Pregnancy-Induced; Pregnancy; Stroke

2019
Views and preferences of medical professionals and pregnant women about a novel primary prevention intervention for hypertensive disorders of pregnancy: a qualitative study.
    Reproductive health, 2019, May-02, Volume: 16, Issue:1

    Topics: Adult; Aspirin; Attitude of Health Personnel; Calcium; Decision Making; Female; General Practitioner

2019
Protein S deficiency complicated pregnancy in women with recurrent pregnancy loss.
    Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2016, Volume: 32, Issue:8

    Topics: Abortion, Habitual; Adult; Antibodies, Antiphospholipid; Aspirin; Birth Weight; Comorbidity; Drug Th

2016
Management of pregnancies complicated by hypertensive disorders of pregnancy: Could we do better?
    The Australian & New Zealand journal of obstetrics & gynaecology, 2017, Volume: 57, Issue:3

    Topics: Adult; Antihypertensive Agents; Aspirin; Chronic Disease; Female; Guideline Adherence; Humans; Hyper

2017
Low-molecular-weight heparin and aspirin use in relation to pregnancy outcome in women with systemic lupus erythematosus and antiphospholipid syndrome: A cohort study.
    Hypertension in pregnancy, 2017, Volume: 36, Issue:1

    Topics: Adult; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Databases, Factual; Female; Heparin, Low-

2017
Aspirin adherence during high-risk pregnancies, a questionnaire study.
    Pregnancy hypertension, 2016, Volume: 6, Issue:4

    Topics: Adult; Aspirin; Female; Fetal Death; Fetal Growth Retardation; Health Knowledge, Attitudes, Practice

2016
Post-pregnancy aspirin resistance appears not to be related with recurrent hypertensive disorders of pregnancy.
    European journal of obstetrics, gynecology, and reproductive biology, 2017, Volume: 210

    Topics: Adult; Aspirin; Drug Resistance; Female; Fibrinolytic Agents; Follow-Up Studies; Humans; Hypertensio

2017
A case of hypertension with virilisation during pregnancy.
    The Australian & New Zealand journal of obstetrics & gynaecology, 2010, Volume: 50, Issue:6

    Topics: Adult; Aspirin; Brenner Tumor; Calcium; Cesarean Section; Dehydroepiandrosterone Sulfate; Dietary Su

2010
Stroke- and pregnancy-induced hypertensive syndromes.
    Women's health (London, England), 2011, Volume: 7, Issue:3

    Topics: Adult; Antihypertensive Agents; Aspirin; Female; Fibrinolytic Agents; Humans; Hypertension, Pregnanc

2011
Prevention of perinatal death with low-dose aspirin in developing countries.
    Hypertension research : official journal of the Japanese Society of Hypertension, 2011, Volume: 34, Issue:10

    Topics: Aspirin; Female; Humans; Hypertension, Pregnancy-Induced; Platelet Aggregation Inhibitors; Pre-Eclam

2011
Prevention of gravidic endothelial hypertension by aspirin treatment administered from the 8th week of gestation.
    Hypertension research : official journal of the Japanese Society of Hypertension, 2011, Volume: 34, Issue:10

    Topics: Adult; Aspirin; Birth Weight; Dose-Response Relationship, Drug; Endothelium, Vascular; Female; Fetal

2011